{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:00:39Z","timestamp":1784840439157,"version":"3.55.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AlSalam University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glycogen synthase kinase-3\u03b2 (GSK-3\u03b2) is a key therapeutic target for Alzheimer\u2019s disease, but identifying safe, brain-penetrant inhibitors remains difficult. This study aimed to discover novel CNS-active GSK-3\u03b2 inhibitors using a rigorous multi-tier computational pipeline. The workflow combined ligand-based and structure-based pharmacophore modeling, virtual screening of the ZINCPharmer database, AutoDock Vina docking, ADME and blood-brain barrier (BBB) filtering with SwissADME, toxicity prediction using ProTox-3.0, and validation by 100-ns molecular dynamics simulations with MM\/GBSA and MM\/PBSA free energy calculations. Pharmacophore screening with a\u2009\u2264\u20091.0 \u00c5 RMSD cutoff identified 1,085 ligand-based and 36 structure-based hits. After docking and developability filtering, two BBB-permeant candidates were prioritized:\n                    <jats:bold>SB1<\/jats:bold>\n                    , a structure-based hit (predicted LD\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u20092500\u00a0mg\/kg, toxicity class 5), and\n                    <jats:bold>LB1<\/jats:bold>\n                    , a ligand-based hit (predicted LD\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u2009521\u00a0mg\/kg, toxicity class 4). Molecular dynamics confirmed stable binding for both compounds. MM\/GBSA analysis showed favorable binding free energies for\n                    <jats:bold>SB1<\/jats:bold>\n                    (-27.68\u00a0kcal\/mol) and\n                    <jats:bold>LB1<\/jats:bold>\n                    (-25.74\u00a0kcal\/mol), both surpassing the co-crystallized reference (-8.75\u00a0kcal\/mol). These findings identify\n                    <jats:bold>SB1<\/jats:bold>\n                    and\n                    <jats:bold>LB1<\/jats:bold>\n                    as promising, safe, and brain-penetrant GSK-3\u03b2 lead compounds for experimental validation in Alzheimer\u2019s disease.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-56505-6","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:08:37Z","timestamp":1784830117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In silico pipeline for GSK 3\u03b2 inhibitor discovery in Alzheimer\u2019s disease using pharmacophore screening, docking, ADME filtering, and MD validation"],"prefix":"10.1038","volume":"16","author":[{"given":"Mahmoud S.","family":"Elkotamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed K.","family":"Elgohary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Alkotami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Eldesouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab M.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr A.","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud F.","family":"Abo-Ashour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haytham O.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagdy M.","family":"Eldehna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem A.","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"56505_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared, A. A., Byrnes, M. J., White, L. A. & Zhang, Q. Alzheimer\u2019s disease: epidemiology and clinical progression. Neurol. Ther. 11, 553\u2013569 (2022).","journal-title":"Neurol. therapy"},{"key":"56505_CR2","unstructured":"Yin, M. et al. The global, regional, and national burden and attributable risk factors of Alzheimer\u2019s disease and other dementias, 1990\u20132021: A systematic analysis for the Global Burden of Disease Study. J. Alzheimer\u2019s Dis. 13872877251360221 (2024)."},{"key":"56505_CR3","doi-asserted-by":"publisher","first-page":"117158","DOI":"10.1016\/j.ejmech.2024.117158","volume":"283","author":"MS Elkotamy","year":"2025","unstructured":"Elkotamy, M. S. et al. Design, synthesis, and evaluation of novel benzofuran and pyrazole-based derivatives as dual AChE\/BuChE inhibitors with antioxidant properties for Alzheimer\u2019s disease management. Eur. J. Med. Chem. 283, 117158 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"56505_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.12688\/f1000research.50786.1","volume":"10","author":"SF Javaid","year":"2021","unstructured":"Javaid, S. F., Giebel, C., Khan, M. A. & Hashim, M. J. Epidemiology of Alzheimer\u2019s disease and other dementias: Rising global burden and forecasted trends. F1000Research 10, 425 (2021).","journal-title":"F1000Research"},{"key":"56505_CR5","doi-asserted-by":"publisher","first-page":"e14818","DOI":"10.1111\/cns.14818","volume":"GSK3","author":"J Zhao","year":"2024","unstructured":"Zhao, J. et al. A potential target and pending issues for treatment of Alzheimer\u2019s disease. CNS Neurosci. Ther. 30. GSK3, e14818 (2024).","journal-title":"CNS Neurosci. Ther. 30"},{"key":"56505_CR6","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3390\/cells10040721","volume":"10","author":"CL Sayas","year":"2021","unstructured":"Sayas, C. L. & \u00c1vila, J. GSK-3 and Tau: A key duet in Alzheimer\u2019s disease. Cells 10, 721 (2021).","journal-title":"Cells"},{"key":"56505_CR7","doi-asserted-by":"publisher","first-page":"792364","DOI":"10.3389\/fnmol.2021.792364","volume":"14","author":"SM Arciniegas Ruiz","year":"2022","unstructured":"Arciniegas Ruiz, S. M. & Eldar-Finkelman, H. Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward. Front. Mol. Neurosci. 14, 792364 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"56505_CR8","doi-asserted-by":"crossref","unstructured":"Koistinaho, J., Malm, T. & Goldsteins, G. Glycogen synthase kinase-3\u03b2: A mediator of inflammation in Alzheimer\u2032 s disease? Int. J. Alzheimer\u2019s Dis. 129753 (2011).","DOI":"10.4061\/2011\/129753"},{"key":"56505_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/jnc.12203","volume":"125","author":"B Georgievska","year":"2013","unstructured":"Georgievska, B. et al. AZD 1080, a novel GSK 3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J. Neurochem. 125, 446\u2013456 (2013).","journal-title":"J. Neurochem."},{"key":"56505_CR10","doi-asserted-by":"publisher","first-page":"9601","DOI":"10.1002\/anie.201603797","volume":"55","author":"SH Liang","year":"2016","unstructured":"Liang, S. H. et al. Discovery of a highly selective glycogen synthase kinase-3 inhibitor (PF\u201004802367) that modulates tau phosphorylation in the brain: Translation for PET neuroimaging. Angew. Chem. Int. Ed. 55, 9601\u20139605 (2016).","journal-title":"Angew. Chem. Int. Ed."},{"key":"56505_CR11","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.1002\/jcb.26788","volume":"119","author":"YD Zhang","year":"2018","unstructured":"Zhang, Y. D. et al. SB-216763, a GSK\u20103\u03b2 inhibitor, protects against aldosterone\u2010induced cardiac, and renal injury by activating autophagy. J. Cell. Biochem. 119, 5934\u20135943 (2018).","journal-title":"J. Cell. Biochem."},{"key":"56505_CR12","doi-asserted-by":"publisher","first-page":"e70056","DOI":"10.1002\/brb3.70056","volume":"14","author":"KX Zhang","year":"2024","unstructured":"Zhang, K. X. et al. Danggui Shaoyao San alleviates early cognitive impairment in Alzheimer\u2019s disease mice through IRS1\/GSK3\u03b2\/Wnt3a-\u03b2\u2010catenin pathway. Brain Behav. 14, e70056 (2024).","journal-title":"Brain Behav."},{"key":"56505_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1055\/s-0044-100186","volume":"68","author":"TL Mathuram","year":"2018","unstructured":"Mathuram, T. L., Reece, L. M. & Cherian, K. M. GSK-3 inhibitors: a double-edged sword?\u2013An update on tideglusib. Drug Res. 68, 436\u2013443 (2018).","journal-title":"Drug Res."},{"key":"56505_CR14","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1016\/j.bmc.2018.07.012","volume":"26","author":"HJ Winfield","year":"2018","unstructured":"Winfield, H. J. et al. Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition. Bioorg. Med. Chem. 26, 4209\u20134224 (2018).","journal-title":"Bioorg. Med. Chem."},{"key":"56505_CR15","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.bmc.2009.01.019","volume":"17","author":"M Saitoh","year":"2009","unstructured":"Saitoh, M. et al. Design, synthesis and structure\u2013activity relationships of 1, 3, 4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3\u03b2. Bioorg. Med. Chem. 17, 2017\u20132029 (2009).","journal-title":"Bioorg. Med. Chem."},{"key":"56505_CR16","doi-asserted-by":"publisher","first-page":"e70009","DOI":"10.1002\/ddr.70009","volume":"85","author":"FA Binjubair","year":"2024","unstructured":"Binjubair, F. A. et al. Molecular docking, DFT and antiproliferative properties of 4-(3, 4\u2010dimethoxyphenyl) \u2013\u20093\u2010(4\u2010methoxyphenyl) \u2013\u20091\u2010phenyl\u20101H\u2010pyrazolo [3, 4\u2010b] pyridine as potent anticancer agent with CDK2 and PIM1 inhibition potency. Drug Dev. Res. 85, e70009 (2024).","journal-title":"Drug Dev. Res."},{"key":"56505_CR17","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.2174\/1568026614666140929124445","volume":"14","author":"E Lionta","year":"2014","unstructured":"Lionta, E., Spyrou, G., Vassilatis, K., Cournia, Z. & D. & Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr. Top. Med. Chem. 14, 1923\u20131938 (2014).","journal-title":"Curr. Top. Med. Chem."},{"key":"56505_CR18","doi-asserted-by":"publisher","first-page":"114766","DOI":"10.1016\/j.ejmech.2022.114766","volume":"243","author":"NM Tripathi","year":"2022","unstructured":"Tripathi, N. M. & Bandyopadhyay, A. High throughput virtual screening (HTVS) of peptide library: Technological advancement in ligand discovery. Eur. J. Med. Chem. 243, 114766 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"56505_CR19","doi-asserted-by":"publisher","first-page":"1800118","DOI":"10.1002\/minf.201800118","volume":"38","author":"EH Mokrani","year":"2019","unstructured":"Mokrani, E. H. et al. Identification of new potent acetylcholinesterase inhibitors using virtual screening and in vitro approaches. Mol. Inf. 38, 1800118 (2019).","journal-title":"Mol. Inf."},{"key":"56505_CR20","unstructured":"Al-Warhi, T. et al. Design and Synthesis of Indole-Based Imidazo [1, 2-a] pyridine derivatives as antiseizure candidates: Evaluation in chemically induced seizure models and in vitro antioxidant assays. ACS Chem. Neurosci. (2026)."},{"key":"56505_CR21","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.2174\/0115701808306787240709073814","volume":"21","author":"A Guendouze","year":"2024","unstructured":"Guendouze, A., Mokrani, E. H., Benslama, O. & Lekmine, S. Exploring the potential of avenanthramides and their analogues as \u03b1-glucosidase inhibitors for type 2 diabetes treatment utilizing virtual screening, molecular dynamics, and drug-likeness predictions. Lett. Drug Des. Discovery. 21, 3858\u20133871 (2024).","journal-title":"Lett. Drug Des. Discovery"},{"key":"56505_CR22","doi-asserted-by":"publisher","first-page":"e202400482","DOI":"10.1002\/cbdv.202400482","volume":"22","author":"A Slimani","year":"2025","unstructured":"Slimani, A. et al. Phytochemical characterization and assessment of antioxidant and anti-alzheimer effects of Algerian Seseli tortuosum. Chem. Biodivers. 22, e202400482 (2025).","journal-title":"Chem. Biodivers."},{"key":"56505_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/3527609164.ch2","volume":"32","author":"K Poptodorov","year":"2006","unstructured":"Poptodorov, K., Luu, T. & Hoffmann, R. D. Pharmacophore model generation software tools. Pharmacophores Pharmacophore Searches. 32, 15\u201347 (2006).","journal-title":"Pharmacophores Pharmacophore Searches"},{"key":"56505_CR24","doi-asserted-by":"crossref","unstructured":"Qing, X. et al. Pharmacophore modeling: advances, limitations, and current utility in drug discovery. J. Recept. Ligand Channel Res., 81\u201392 (2014).","DOI":"10.2147\/JRLCR.S46843"},{"key":"56505_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.4155\/fmc.11.18","volume":"3","author":"GL Wilson","year":"2011","unstructured":"Wilson, G. L. & Lill, M. A. Integrating structure-based and ligand-based approaches for computational drug design. Future Med. Chem. 3, 735\u2013750 (2011).","journal-title":"Future Med. Chem."},{"key":"56505_CR26","doi-asserted-by":"publisher","first-page":"W442","DOI":"10.1093\/nar\/gkw287","volume":"44","author":"J Sunseri","year":"2016","unstructured":"Sunseri, J. & Koes, D. R. Pharmit: interactive exploration of chemical space. Nucleic Acids Res. 44, W442\u2013W448 (2016).","journal-title":"Nucleic Acids Res."},{"key":"56505_CR27","doi-asserted-by":"publisher","first-page":"W409","DOI":"10.1093\/nar\/gks378","volume":"40","author":"DR Koes","year":"2012","unstructured":"Koes, D. R. & Camacho, C. J. ZINCPharmer: pharmacophore search of the ZINC database. Nucleic Acids Res. 40, W409\u2013W414 (2012).","journal-title":"Nucleic Acids Res."},{"key":"56505_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle, N. M. et al. Open Babel: An open chemical toolbox. J. Cheminform. 3, 33 (2011).","journal-title":"J. Cheminform."},{"key":"56505_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"56505_CR30","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."},{"key":"56505_CR31","doi-asserted-by":"publisher","first-page":"W513","DOI":"10.1093\/nar\/gkae303","volume":"52","author":"P Banerjee","year":"2024","unstructured":"Banerjee, P., Kemmler, E., Dunkel, M. & Preissner, R. ProTox 3.0: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 52, W513\u2013W520 (2024).","journal-title":"Nucleic Acids Res."},{"key":"56505_CR32","doi-asserted-by":"publisher","first-page":"140462","DOI":"10.1016\/j.ijbiomac.2025.140462","volume":"303","author":"MS Elkotamy","year":"2025","unstructured":"Elkotamy, M. S. et al. Development of pyrazolo [1, 5-a] pyrimidine-grafted coumarins as selective carbonic anhydrase inhibitors and tubulin polymerization inhibitors with potent anticancer activity. Int. J. Biol. Macromol. 303, 140462 (2025).","journal-title":"Int. J. Biol. Macromol."},{"key":"56505_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"GROMACS","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1. GROMACS, 19\u201325 (2015).","journal-title":"SoftwareX 1"},{"key":"56505_CR34","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1021\/acs.jcim.3c01053","volume":"63","author":"M Bugnon","year":"2023","unstructured":"Bugnon, M. et al. SwissParam 2023: a modern web-based tool for efficient small molecule parametrization. J. Chem. Inf. Model. 63, 6469\u20136475 (2023).","journal-title":"J. Chem. Inf. Model."},{"key":"56505_CR35","doi-asserted-by":"publisher","first-page":"10096","DOI":"10.1063\/1.1808117","volume":"121","author":"DJ Price","year":"2004","unstructured":"Price, D. J. & Brooks, I. I. I. A modified TIP3P water potential for simulation with Ewald summation. J. Chem. Phys. 121, 10096\u201310103 (2004).","journal-title":"J. Chem. Phys."},{"key":"56505_CR36","doi-asserted-by":"publisher","first-page":"108247","DOI":"10.1016\/j.bioorg.2025.108247","volume":"157","author":"MS Elkotamy","year":"2025","unstructured":"Elkotamy, M. S. et al. Design, synthesis, and molecular dynamics-driven evaluation of quinoline-sulfonamide derivatives as potent and selective EGFR inhibitors with promising anti-cancer efficacy and safety profiles. Bioorg. Chem. 157, 108247 (2025).","journal-title":"Bioorg. Chem."},{"key":"56505_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1021\/ci900349y","volume":"50","author":"N Weill","year":"2010","unstructured":"Weill, N. & Rognan, D. Alignment-free ultra-high-throughput comparison of druggable protein\u2013 ligand binding sites. J. Chem. Inf. Model. 50, 123\u2013135 (2010).","journal-title":"J. Chem. Inf. Model."},{"key":"56505_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00894-020-04577-0","volume":"26","author":"T Lu","year":"2020","unstructured":"Lu, T. & van der Chen, Q. Waals potential: an important complement to molecular electrostatic potential in studying intermolecular interactions. J. Mol. Model. 26, 315 (2020).","journal-title":"J. Mol. Model."},{"key":"56505_CR39","doi-asserted-by":"publisher","first-page":"14231","DOI":"10.1021\/jacs.4c17497","volume":"147","author":"H Qi","year":"2025","unstructured":"Qi, H. et al. Steric complementarity drives strong co-assembly of short peptide stereoisomers. J. Am. Chem. Soc. 147, 14231\u201314243 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"56505_CR40","doi-asserted-by":"publisher","first-page":"107644","DOI":"10.1016\/j.bioorg.2024.107644","volume":"151","author":"MS Elkotamy","year":"2024","unstructured":"Elkotamy, M. S. et al. Novel imidazo [2, 1-b] thiazoles and imidazo [1, 2-a] pyridines tethered with indolinone motif as VEGFR-2 inhibitors and apoptotic inducers: Design, synthesis and biological evaluations. Bioorg. Chem. 151, 107644 (2024).","journal-title":"Bioorg. Chem."},{"key":"56505_CR41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/157340911795677602","volume":"7","author":"XY Meng","year":"2011","unstructured":"Meng, X. Y., Zhang, H. X., Mezei, M. & Cui, M. Molecular docking: a powerful approach for structure-based drug discovery. Curr. Comput.-Aided Drug Design. 7, 146\u2013157 (2011).","journal-title":"Curr. Comput.-Aided Drug Design"},{"key":"56505_CR42","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/bioinformatics\/btq112","volume":"26","author":"PJ Ballester","year":"2010","unstructured":"Ballester, P. J. & Mitchell, J. B. A machine learning approach to predicting protein\u2013ligand binding affinity with applications to molecular docking. Bioinformatics 26, 1169\u20131175 (2010).","journal-title":"Bioinformatics"},{"key":"56505_CR43","doi-asserted-by":"crossref","unstructured":"Elkotamy, M. S. et al. Rationally designed Pyrazolo [1, 5-a] pyrimidines as dual inhibitors of CA IX\/XII and CDK6: A novel approach for NSCLC treatment. European J. Med. Chem. 117752 (2025).","DOI":"10.1016\/j.ejmech.2025.117752"},{"key":"56505_CR44","first-page":"181","volume":"68","author":"MS Elkotamy","year":"2025","unstructured":"Elkotamy, M. S., Abdelrahman, M. A., Eldehna, W. M., Abdel-Aziz, H. A. & Abou-Seri, S. M. Synthesis and biological evaluation of Coumarin derivatives with promising anti-cancer activity: Computational kinase profiling and molecular modeling analysis. Egypt. J. Chem. 68, 181\u2013197 (2025).","journal-title":"Egypt. J. Chem."},{"key":"56505_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2015.03.014","volume":"86","author":"L Tao","year":"2015","unstructured":"Tao, L. et al. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools. Adv. Drug Deliv. Rev. 86, 83\u2013100 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"56505_CR46","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/ddr.10100","volume":"56","author":"E Planel","year":"2002","unstructured":"Planel, E., Sun, X. & Takashima, A. Role of GSK-3\u03b2 in Alzheimer\u2019s disease pathology. Drug Dev. Res. 56, 491\u2013510 (2002).","journal-title":"Drug Dev. Res."},{"key":"56505_CR47","doi-asserted-by":"publisher","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","volume":"22","author":"SV Ambudkar","year":"2003","unstructured":"Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E. & Gottesman, M. M. P-glycoprotein: from genomics to mechanism. Oncogene 22, 7468\u20137485 (2003).","journal-title":"Oncogene"},{"key":"56505_CR48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/jop.2021.0069","volume":"38","author":"TK Karami","year":"2022","unstructured":"Karami, T. K., Hailu, S., Feng, S., Graham, R. & Gukasyan, H. J. Eyes on lipinski\u2019s rule of five: a new rule of thumb for physicochemical design space of ophthalmic drugs. J. Ocul. Pharmacol. Ther. 38, 43\u201355 (2022).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"56505_CR49","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.drudis.2016.07.007","volume":"21","author":"MK Bayliss","year":"2016","unstructured":"Bayliss, M. K. et al. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. Drug discovery today. 21, 1719\u20131727 (2016).","journal-title":"Drug discovery today"},{"key":"56505_CR50","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","volume":"99","author":"SA Hollingsworth","year":"2018","unstructured":"Hollingsworth, S. A. & Dror, R. O. Molecular dynamics simulation for all. Neuron 99, 1129\u20131143 (2018).","journal-title":"Neuron"},{"key":"56505_CR51","doi-asserted-by":"crossref","unstructured":"Elkotamy, M. S. et al. Design, synthesis and biological evaluation of pyrazolo [3, 4-b] pyridine derivatives as dual CDK2\/PIM1 inhibitors with potent anti-cancer activity and selectivity. J. Biomol. Struct. Dyn., 1\u201325 (2025).","DOI":"10.1080\/07391102.2025.2475233"},{"key":"56505_CR52","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1021\/cr0404242","volume":"106","author":"V Daggett","year":"2006","unstructured":"Daggett, V. Protein folding\u2013 simulation. Chem. Rev. 106, 1898\u20131916 (2006).","journal-title":"Chem. Rev."},{"key":"56505_CR53","doi-asserted-by":"crossref","unstructured":"Al-Sanea, M. M. et al. Click chemistry synthesis of triazole-grafted quinazolinones as new multi-panel anticancer agents: mechanistic insights into apoptosis and cell cycle arrest in colorectal cancer. Bioorganic Chem., 109846 (2026).","DOI":"10.1016\/j.bioorg.2026.109846"},{"key":"56505_CR54","doi-asserted-by":"crossref","unstructured":"Alqarni, M. H. et al. Structure-guided design and synthesis of Etoricoxib analogues for selective COX-2 inhibition: in vitro assessment and computational insights with prospective in vivo confirmation. Mol. Diversity 1\u201327 (2026).","DOI":"10.1007\/s11030-026-11555-w"},{"key":"56505_CR55","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10822-016-0005-2","volume":"31","author":"K Liu","year":"2017","unstructured":"Liu, K., Watanabe, E. & Kokubo, H. Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations. J. Comput. Aided Mol. Des. 31, 201\u2013211 (2017).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"56505_CR56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jmb.2008.05.006","volume":"380","author":"GD Friedland","year":"2008","unstructured":"Friedland, G. D., Linares, A. J., Smith, C. A. & Kortemme, T. A simple model of backbone flexibility improves modeling of side-chain conformational variability. J. Mol. Biol. 380, 757\u2013774 (2008).","journal-title":"J. Mol. Biol."},{"key":"56505_CR57","doi-asserted-by":"crossref","unstructured":"Elkotamy, M. S. et al. Multi-target pyrazolopyrimidine-coumarin derivatives as potent CA IX\/XII and tubulin polymerization inhibitors: Design, synthesis, and biological evaluation. Eur. J. Med. Chem. 118789 (2026).","DOI":"10.1016\/j.ejmech.2026.118789"},{"key":"56505_CR58","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1080\/07391102.2020.1805362","volume":"39","author":"ND Elangovan","year":"2021","unstructured":"Elangovan, N. D., Dhanabalan, A. K., Gunasekaran, K., Kandimalla, R. & Sankarganesh, D. Screening of potential drug for Alzheimer\u2019s disease: A computational study with GSK-3 \u03b2 inhibition through virtual screening, docking, and molecular dynamics simulation. J. Biomol. Struct. Dyn. 39, 7065\u20137079 (2021).","journal-title":"J. Biomol. Struct. Dynamics"},{"key":"56505_CR59","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3390\/molecules27072105","volume":"27","author":"HA Filipe","year":"2022","unstructured":"Filipe, H. A. & Loura, L. M. Molecular dynamics simulations: advances and applications. Molecules 27, 2105 (2022).","journal-title":"Molecules"},{"key":"56505_CR60","doi-asserted-by":"crossref","unstructured":"Eldehna, W. M. et al. 2-(Piperidin-1-yl)-N-(4-sulfamoylphenyl) acetamide derivatives as novel inhibitors of cancer-associated carbonic anhydrase isoforms IX and XII. Int. J. Biol. Macromol. 146776 (2025).","DOI":"10.1016\/j.ijbiomac.2025.146776"},{"key":"56505_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/2277-5706.241211","volume":"1","author":"S Sandeep","year":"2012","unstructured":"Sandeep, S., Priyadarshini, V., Pradhan, D., Munikumar, M. & Umamaheswari, A. Docking and molecular dynamics simulations studies of human protein kinase catalytic subunit alpha with antagonist. J. Clin. Sci. Res. 1, 15\u201323 (2012).","journal-title":"J. Clin. Sci. Res."},{"key":"56505_CR62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00894-015-2627-z","volume":"21","author":"P Czele\u0144","year":"2015","unstructured":"Czele\u0144, P. & Szefler, B. Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3\u03b2 and CDK-2. J. Mol. Model. 21, 74 (2015).","journal-title":"J. Mol. Model."},{"key":"56505_CR63","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s12033-023-00831-x","volume":"66","author":"AM da Fonseca","year":"2024","unstructured":"da Fonseca, A. M. et al. Screening of potential inhibitors targeting the main protease structure of SARS-CoV-2 via molecular docking, and approach with molecular dynamics, RMSD, RMSF, H-bond, SASA and MMGBSA. Mol. Biotechnol. 66, 1919\u20131933 (2024).","journal-title":"Mol. Biotechnol."},{"key":"56505_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.procs.2019.08.181","volume":"156","author":"M Arnittali","year":"2019","unstructured":"Arnittali, M., Rissanou, A. N. & Harmandaris, V. Structure of biomolecules through molecular dynamics simulations. Proc. Comput. Sci. 156, 69\u201378 (2019).","journal-title":"Procedia Comput. Sci."},{"key":"56505_CR65","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3390\/molecules22112029","volume":"22","author":"D Gioia","year":"2017","unstructured":"Gioia, D., Bertazzo, M., Recanatini, M., Masetti, M. & Cavalli, A. Dynamic docking: a paradigm shift in computational drug discovery. Molecules 22, 2029 (2017).","journal-title":"Molecules"},{"key":"56505_CR66","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1021\/acs.jcim.7b00412","volume":"57","author":"K Liu","year":"2017","unstructured":"Liu, K. & Kokubo, H. Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations: A cross-docking study. J. Chem. Inf. Model. 57, 2514\u20132522 (2017).","journal-title":"J. Chem. Inf. Model."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56505-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:01:50Z","timestamp":1784836910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56505-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56505"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56505-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23100"}}